QuidelOrtho Corporation and BÜHLMANN Laboratories AG announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as a MicroTip Partnership Assay. These particle-enhanced turbidimetric immunoassays are designed to enhance patient diagnosis.
The fCAL turbo assay measures fecal calprotectin, aiding in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome. The fPELA turbo assay measures fecal pancreatic elastase, assisting in the determination of pancreatic insufficiency.
These assays offer rapid results in less than 10 minutes, wide reportable ranges, and 90-day on-analyzer stability, compatible with VITROS Automation Solutions. This collaboration expands QuidelOrtho's diagnostic menu, contributing to better management of gastrointestinal health and potentially reducing the need for invasive procedures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.